ProQR Therapeutics announced progress in its RNA editing pipeline, highlighting the upcoming target engagement data for its lead program AX-0810 expected in the first half of 2026. The company selected biliary atresia as the initial Phase 2 indication for AX-0810 and revealed new programs AX-0811 and AX-0422 advancing toward clinical trials. ProQR also emphasized the continued development of its Axiomer platform, supported by AI and a partnership with Ginkgo Bioworks, aiming for multiple clinical data readouts within its current cash runway through mid-2027. This progress signals ProQR's commitment to pioneering RNA therapies for rare and prevalent diseases with unmet needs.
Investment banks Scotiabank and Bernstein have lowered their price targets for Comcast due to increased competition from new players like SpaceX's Starlink and valuation risks. Comcast is also undergoing a major strategic shift by spinning off its NB...
Elevance Health reported strong Q2 2026 results with earnings per share of $7.45, surpassing analyst estimates of around $6.20. Revenue also exceeded expectations at $49.83 billion, marking consistent quarterly outperformance. The company raised its ...
Lotto.com has appointed Ruxandra Tereanu as Chief Operating Officer and Amanda Coyle as Vice President of Human Resources to strengthen its leadership team amid ongoing expansion in the US digital lottery market. Tereanu brings 13 years of experience...
Worldline has announced a conference call to discuss its H1 2026 financial results on July 30, 2026, at 6:30 pm CET. The event will be accessible via webcast, and sell-side analysts can participate in a Q&A session by pre-registering. The press relea...
Ipsen Pharma conducted a share buy-back program from July 6 to July 10, 2026, repurchasing a total of 28,541 shares. The average purchase price during this period was €166.05 per share. This buy-back activity reflects Ipsen's strategy to manage its c...
